Yunji (YJ)
NASDAQ:YJ
Want to see YJ full AI Analyst Report?
Top Page
Yunji
(NASDAQ:YJ)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.50
▲(16.28% Upside)
Action:ReiteratedDate:05/01/26
The score is primarily held back by poor financial performance, including steep revenue declines, widening losses, and persistent cash burn. Technical indicators are neutral-to-slightly constructive, but they do not offset weak fundamentals, and valuation is difficult to justify with negative earnings and no dividend support.
Positive Factors
Private‑label pivot
Yunji's deliberate pivot to private‑label health products aligns its assortment with China's national health strategy and increases control over pricing, supply and quality. Over months this structural shift can support higher margin capture, simplify supplier management and focus resources on profitable SKUs if execution persists.
Negative Factors
Revenue contraction
Multi‑year top‑line decline reduces scale economics critical for e‑commerce marketplaces, weakening supplier leverage, marketing efficiency and customer acquisition ROI. Persistent revenue shrinkage undermines the revenue base that private‑label and cost actions must rebuild, making sustainable recovery more difficult over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Private‑label pivot
Yunji's deliberate pivot to private‑label health products aligns its assortment with China's national health strategy and increases control over pricing, supply and quality. Over months this structural shift can support higher margin capture, simplify supplier management and focus resources on profitable SKUs if execution persists.
Read all positive factors
Yunji (YJ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.87M
Dividend YieldN/A
Average Volume (3M)6.30K
Price to Earnings (P/E)―
Beta (1Y)0.31
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees363
SectorConsumer Cyclical
Sector Strength84
IndustrySpecialty Retail
Share Statistics
EPS (TTM)-26.32
Shares Outstanding2,550,640
10 Day Avg. Volume2,921
30 Day Avg. Volume6,304
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00230
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.66
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yunji Business Overview & Revenue Model
Company Description
Yunji Inc. operates a social e-commerce platform in the People's Republic of China. It offers a range of product categories that cater various daily needs of users and their households, including beauty and personal care, household goods, cloths, ...
How the Company Makes Money
null...
Yunji Earnings Call Summary
Earnings Call Date:Aug 21, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:May 28, 2026
Earnings Call Sentiment Neutral
While Yunji has achieved notable successes in product launches and brand expansion, the company faced significant financial challenges, including a decline in revenue and increased net loss. The strategic initiatives show promise but are juxtaposed against a backdrop of financial difficulties.Positive Updates
Successful Launch of Youjiang Organic Milk
Youjiang Organic Milk achieved RMB 5 million in sales at launch, establishing Yunji's health-focused brand awareness among consumers.
Negative Updates
Revenue Decline
Total revenue decreased to RMB 158.3 million from RMB 233.8 million a year ago, mainly due to softer consumer confidence and strategic product selection refinement.
Read all updates
Q2-2025 Updates
Positive
Negative
Successful Launch of Youjiang Organic Milk
Youjiang Organic Milk achieved RMB 5 million in sales at launch, establishing Yunji's health-focused brand awareness among consumers.
Read all positive updates
Company Guidance
During Yunji's First Half 2025 Earnings Conference Call, CEO Shanglue Xiao emphasized the company's commitment to an organic health strategy amidst challenging market conditions and declining consumer confidence, with the goal of establishing Yunji's future growth prospects. The flagship product, Youjiang Organic Milk, launched with RMB 5 million in sales, while other successful products included slimming coffee with over RMB 10 million, probiotics bolus nearing RMB 7 million, and freeze-dried sea buckthorn powder exceeding RMB 5 million in sales. The beauty brand SUYE also performed well, with the PRO-XLANE FIRMING Series generating over RMB 10 million. Financial highlights included a total revenue of RMB 158.3 million, down from RMB 233.8 million the previous year, with a gross margin holding steady at 47.3%. Operating expenses rose to RMB 179.4 million, leading to a net loss of RMB 100.7 million, compared to RMB 8 million a year ago. Despite these challenges, the company maintained a cash position of RMB 217.1 million, focusing on optimizing cost structures and improving profitability.Yunji Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 779.75M | 317.02M | 417.65M | 640.21M | 1.15B | 2.16B |
| Gross Profit | 356.02M | 140.79M | 206.34M | 307.44M | 502.54M | 811.98M |
| EBITDA | -73.60M | -122.47M | -103.53M | -141.07M | -93.59M | 18.65M |
| Net Income | -130.60M | -133.28M | -123.11M | -165.13M | -131.34M | 131.97M |
Balance Sheet | ||||||
| Total Assets | 1.67B | 1.21B | 1.35B | 1.55B | 1.89B | 2.35B |
| Cash, Cash Equivalents and Short-Term Investments | 528.93M | 193.36M | 219.37M | 524.74M | 626.64M | 947.26M |
| Total Debt | 18.56M | 43.18M | 11.65M | 14.50M | 1.31M | 8.69M |
| Total Liabilities | 406.81M | 273.75M | 274.41M | 362.69M | 536.51M | 871.46M |
| Stockholders Equity | 1.27B | 935.23M | 1.08B | 1.19B | 1.36B | 1.48B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -126.58M | -318.62M | -200.67M | -309.08M | -112.97M |
| Operating Cash Flow | 0.00 | -57.78M | -126.08M | -188.26M | -216.82M | -25.99M |
| Investing Cash Flow | 0.00 | -88.23M | -166.33M | 294.04M | 92.56M | -513.79M |
| Financing Cash Flow | 0.00 | 38.70M | -13.32M | -25.33M | -94.56M | -463.00K |
Yunji Technical Analysis
Positive
1.29
Price Trends
1.61
Positive
1.52
Positive
1.68
Positive
Market Momentum
0.02
Negative
53.14
Neutral
83.15
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YJ, the sentiment is Positive. The current price of 1.29 is below the 20-day moving average (MA) of 1.70, below the 50-day MA of 1.61, and below the 200-day MA of 1.68, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.14 is Neutral, neither overbought nor oversold. The STOCH value of 83.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for YJ.
Yunji Risk Analysis
Yunji disclosed 93 risk factors in its most recent earnings report. Yunji reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Yunji Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
56 Neutral | $166.65M | -7.20 | -6.45% | ― | 5.82% | -35.69% | |
49 Neutral | $18.72M | ― | -9.51% | ― | 6.50% | ― | |
47 Neutral | $8.87M | ― | ― | ― | ― | ― | |
| ― | $5.83M | -0.43 | 12.11% | ― | 4368.01% | -109.28% | |
49 Neutral | $5.53M | -0.25 | ― | ― | 24.08% | 21.73% | |
40 Underperform | $6.81M | 0.25 | -373.22% | ― | -67.70% | 44.67% |
* Consumer Cyclical Sector Average
YJ
Yunji
1.80
0.06
3.45%
BZUN
Baozun
2.75
-0.10
-3.51%
MOGU
Mogu
2.29
0.05
2.23%
WNW
Meiwu Technology Company Limited
4.38
-205.62
-97.91%
JWEL
Jowell Global
2.55
0.69
37.04%
WBUY
Webuy Global
1.34
-1.89
-58.51%
Yunji Corporate Events
Yunji Narrows Losses in 2025 as It Accelerates Pivot to Private-Label Health Products
Mar 27, 2026
Yunji on March 27, 2026 reported unaudited results for the second half and full year 2025, showing revenue declines as it deliberately scaled back its marketplace business and refined product and supplier selection. The platform maintained a high ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.